Oppenheimer Weighs in on bluebird bio, Inc.’s FY2017 Earnings (BLUE)
bluebird bio, Inc. (NASDAQ:BLUE) – Analysts at Oppenheimer issued their FY2017 EPS estimates for bluebird bio in a report released on Wednesday. Oppenheimer analyst M. Breidenbach expects that the biotechnology company will post earnings of ($6.93) per share for the year. Oppenheimer has a “Market Perform” rating on the stock. Oppenheimer also issued estimates for bluebird bio’s Q4 2018 earnings at ($1.85) EPS, FY2018 earnings at ($7.05) EPS and FY2019 earnings at ($7.37) EPS.
bluebird bio (NASDAQ:BLUE) last posted its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.68) by ($0.05). The firm had revenue of $7.71 million during the quarter, compared to analysts’ expectations of $8.47 million. bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The firm’s revenue for the quarter was up 397.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($2.07) earnings per share.
Other equities research analysts have also issued research reports about the company. Morgan Stanley raised bluebird bio from an “underweight” rating to an “equal weight” rating in a research note on Friday, November 3rd. Evercore ISI raised bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 target price on the stock in a research note on Monday, October 16th. Maxim Group set a $170.00 target price on bluebird bio and gave the company a “buy” rating in a research note on Friday, November 17th. CIBC initiated coverage on bluebird bio in a research note on Thursday. They issued a “market perform” rating on the stock. Finally, Goldman Sachs Group reissued a “buy” rating and set a $186.00 price target on shares of bluebird bio in a research note on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and thirteen have issued a buy rating to the company’s stock. bluebird bio presently has an average rating of “Hold” and a consensus price target of $157.45.
bluebird bio (NASDAQ BLUE) opened at $179.55 on Monday. The stock has a market capitalization of $8,230.00, a PE ratio of -25.61 and a beta of 2.08. bluebird bio has a 52-week low of $60.95 and a 52-week high of $222.03.
A number of institutional investors have recently bought and sold shares of BLUE. QS Investors LLC boosted its stake in bluebird bio by 70.7% in the 2nd quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 500 shares during the period. Ladenburg Thalmann Financial Services Inc. boosted its stake in bluebird bio by 454.2% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock worth $136,000 after purchasing an additional 813 shares during the period. Bank of Montreal Can boosted its stake in bluebird bio by 118.9% in the 2nd quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 911 shares during the period. Biondo Investment Advisors LLC acquired a new stake in shares of bluebird bio during the 3rd quarter valued at $203,000. Finally, SG Americas Securities LLC boosted its stake in shares of bluebird bio by 17.9% during the 2nd quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 295 shares during the period.
In related news, insider Nick Leschly sold 117,500 shares of the firm’s stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $184.08, for a total transaction of $21,629,400.00. Following the transaction, the insider now owns 293,232 shares in the company, valued at $53,978,146.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jeffrey T. Walsh sold 4,900 shares of the firm’s stock in a transaction that occurred on Tuesday, October 10th. The shares were sold at an average price of $129.94, for a total transaction of $636,706.00. The disclosure for this sale can be found here. Insiders sold 215,082 shares of company stock worth $37,227,332 in the last three months. 3.90% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Oppenheimer Weighs in on bluebird bio, Inc.’s FY2017 Earnings (BLUE)” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://theolympiareport.com/2017/12/25/oppenheimer-weighs-in-on-bluebird-bio-inc-s-fy2017-earnings-blue.html.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with Analyst Ratings Network's FREE daily email newsletter.